Gleevec (Imatinib)

Property	Information
Drug Name	Gleevec (Imatinib)
FDA Approval	Yes (for chronic myelogenous leukemia and other cancers, not specifically approved for gliomas)
Used for	Investigational use in gliomas, specifically targeting overexpression of platelet-derived growth factor receptor (PDGFR)
Clinical Trial Phase	Exploratory/Investigational (Specific phase for gliomas not provided)
Clinical Trial Explanation	Not specified
Common Side Effects	Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population.
OS without	Not specified
OS with	Not applicable; studies focusing on PFS-6 as a primary endpoint
PFS without	Not specified
PFS with	PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR
Usefulness Rating	Investigational (Specific usefulness rating not provided due to varying outcomes and limited glioma-focused trials)
Usefulness Explanation	Not specified
Toxicity Level	Not specified
Toxicity Explanation	Not specified

Notes: Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.

From Ben Williams Book: Not specified

Loading comments...